Nektar Therapeutics
Tracked across 7 events · 513 articles · First seen Jan 29, 2026 · Last active Apr 20, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Nektar Therapeutics announced an upsized $400 million public offering of common stock and pre-funded warrants. This offering is expected to provide capital for general corporate purposes, including research and development, clinical trials for rezpegaldesleukin, and manufacturing costs, which is a positive for the company's future operations.
Feb 10, 2026 · 7 articles
Business
Nektar Therapeutics is facing a class action lawsuit due to allegedly false and misleading statements regarding its REZOLVE-AA trial. The trial's failure to meet statistical significance, attributed to enrollment protocol violations, led to a significant drop in Nektar Therapeutics' stock price.
Mar 06, 2026 · 134 articles
Regulatory
Nektar Therapeutics is facing a class action lawsuit due to alleged false and misleading statements regarding its REZOLVE-AA trial. The company's stock price is expected to suffer as a result of this legal action and the potential negative impact on its product candidate, rezpegaldesleukin.
Apr 03, 2026 · 7 articles
Business
Nektar Therapeutics is facing a federal securities class action lawsuit due to alleged false and misleading statements regarding its REZOLVE-AA trial. The trial's failure to reach statistical significance, attributed to protocol violations, led to a significant drop in Nektar Therapeutics' stock price.
Mar 06, 2026 · 22 articles
Business
Nektar Therapeutics is subject to a class action lawsuit for allegedly failing to follow protocol standards in its REZOLVE-AA trial enrollment, which is expected to negatively impact trial results and overall integrity.
Mar 18, 2026 · 9 articles
+ 2 more events
View on Dashboard
100
The Rosen Law Firm filed a class action lawsuit Nektar TherapeuticsNektar Therapeutics Class...
100
The Rosen Law Firm filed class action lawsuit Nektar TherapeuticsNektar Therapeutics Class...
100
The Schall Law Firm filed a class action lawsuit Nektar TherapeuticsNektar Therapeutics faces...
100
Faruqi & Faruqi, LLP investigating potential claims and filed class action lawsuit Nektar TherapeuticsNektar Therapeutics Faces...
95
Nektar Therapeutics announced failed Phase 2b trial resultsNektar Therapeutics Class...
95
Nektar Therapeutics stock price fellNektar Therapeutics Faces...
95
Faruqi & Faruqi, LLP investigating potential claims and filing class action lawsuit Nektar TherapeuticsNektar Therapeutics Faces...
90
Nektar Therapeutics made false and/or misleading statementsNektar Therapeutics Class...
+ 7 more actions
View on Dashboard
NEWSDESK
Track Nektar Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard